实施共识驱动的质量改进方案以缩短择期颈动脉内膜切除术后住院时间
该质量改进项目通过两个PDSA循环制定并实施标准化方案,包括围术期抗高血压药物管理和术前α1受体阻滞剂使用。干预后住院时间超过1天的失败率从58.3%降至32.8%(P=0.01),约改善40%,30天再入院率无显著差异(6.3% vs 9.4%,P=0.73)。
要点
- 择期颈动脉内膜切除术后住院时间超过1天的失败率由干预前58.3%降至干预后32.8%(P=0.01)。
- 围术期抗高血压方案依从率为89.8%,术前α1受体阻滞剂依从率为78.8%。
- 干预前后30天再入院率无显著差异(6.3% vs 9.4%,P=0.73)。
核心结论
- 共识驱动的质量改进方案在降低择期颈动脉内膜切除术后住院时间方面显示出有希望的结果,主要结局指标约改善40%。
研究设计与样本
- 质量改进项目,包含2个Plan-Do-Study-Act(PDSA)循环,干预前8个月纳入48例患者,干预后12个月纳入64例符合方案标准的患者。
主要发现
- 干预前8个月住院时间超过1天的失败率为58.3%(48例患者)。
- 干预后12个月住院时间超过1天的失败率为32.8%(P=0.01)。
- 干预前住院时间中位数为2天(四分位距1-2天),干预后中位数为1天(四分位距1-2天),P=0.07。
- 干预前30天再入院率为6.3%,干预后为9.4%(P=0.73)。
- 术前抗高血压方案依从率为89.8%,术前α1受体阻滞剂依从率为78.8%,术中低血压发生1例(1.6%)。
临床怎么用
- 作者认为,改善颈动脉内膜切除术后住院时间的更广泛努力应关注术后高血压和尿潴留的最小化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: National guidelines stipulate that postoperative length-of-stay (LOS) after elective carotid endarterectomy (CEA) should not exceed 1 day on average, yet perioperative care coordination gaps may limit the ability for institutions to achieve this goal. Internal review determined that increased LOS after CEA at our institution was frequently attributable to urinary retention or postoperative hypertension. We designed and implemented a quality improvement (QI) protocol aiming to better our institutional performance in postoperative LOS after CEA, consisting of 2 Plan-Do-Study-Act (PDSA) cycles. METHODS: In the first PDSA cycle, a division-wide standardized protocol was developed by which antihypertensive medications were managed preoperatively and through postoperative day (POD) 1. This protocol included dedicated patient outreach with instructions for at-home antihypertensive management through the morning of POD 0. Second, alpha-1-blockade was administered to all male patients preoperatively. All patients receiving an elective CEA performed at our institution by vascular surgeons were included in the protocol. The primary outcome measure was defined percent failure of the LOS >1 day metric, with raw LOS as a secondary outcome measure. Process measures included adherence to the antihypertensive medication protocol and adherence to preoperative alpha-1 blockade. Balance measures included documented intraoperative hypotension and 30-day readmission. Fisher's exact test was used to evaluate relationships between preintervention and postintervention cohorts and the outcome measure. Wilcoxon rank-sum tests were used to evaluate relationships between cohorts and total LOS. RESULTS: Baseline performance on the LOS >1 day metric after elective CEA was 58.3% in the 8 months prior to intervention, across 48 patients. Both PDSA interventions were implemented simultaneously. In the 12 months after intervention, 64 patients met protocol inclusion criteria, including 19 symptomatic patients (29.7%). Process measure success for preoperative antihypertensive regimen adherence was 89.8%. For males not chronically prescribed alpha-1 blockade preoperatively, process measure success for adherence to preoperative alpha-1 blockade was 78.8%. The intraoperative hypotension balance measure occurred in 1 patient (1.6%). Performance on the LOS >1 day outcome measure was improved to 32.8% (P = 0.01). Performance on the raw LOS outcome measure was similar between the preintervention cohort (median 2 days, interquartile range [IQR] 1-2) and postintervention cohort (median 1 day, IQR 1-2, P = 0.07). Performance on the 30-day readmission balance measure was similar between preintervention (6.3%) and postintervention cohorts (9.4%, P = 0.73). CONCLUSIONS: The consensus-driven development and implementation of a QI protocol to reduce postoperative LOS after CEA showed promising results in our institution, with approximately 40% improvement in the primary outcome measure. Wider efforts to improve LOS after CEA should include a focus on minimization of postoperative hypertension and urinary retention.
引用
- Feldman ZM, Lella SK, Lee S, et al. Implementation of a Consensus-Driven Quality Improvement Protocol to Decrease Length of Stay after Elective Carotid Endarterectomy. Ann Vasc Surg. 2023. PMID: 37355013. doi:10.1016/j.avsg.2023.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。